NHS launches world-first cancer vaccine matchmaking program in England
Cancer vaccine trials are now being fast-tracked through a landmark NHS program in England that matches patients with personalized mRNA vaccines built around their individual tumors. The Cancer Vaccine Launch Pad, operating across 30 hospitals, uses the same mRNA technology behind COVID-19 vaccines to design custom treatments targeting each patient’s unique cancer mutations. The program aims to eliminate remaining cancer cells after surgery before they can return. Early immune response data is encouraging, and a 2024 trial showed a 44% reduction in melanoma recurrence when similar vaccines were combined with immunotherapy.









